Dean S, Kendall M J, Potter S, Thompson M H, Jackson D A
Eur J Clin Pharmacol. 1985;28(1):29-33. doi: 10.1007/BF00635704.
Twenty-four hypertensive patients have been studied. All had blood pressure recordings greater than 160/95 mmHg on 3 occasions whilst taking a beta blocker and two other antihypertensive agents in therapeutic doses. Compliance was checked by intermittent urine analysis for the relevant beta-blocker. These difficult to control hypertensives were treated with nadolol alone, nadolol plus indapamide and nadolol plus xipamide each for 2 months in random order. The aim was to reduce the blood pressure to below 160/95 mmHg. The supine blood pressure on nadolol alone (167/100 mmHg) was comparable to that on the previous three drug regimens (157/100 mmHg), the other two treatments were more effective (145/90 and 148/93 mmHg respectively). Hypokalaemia (serum potassium below 3.5 mmol/l) occurred in six individuals but occurred more frequently on xipamide than on indapamide.
对24名高血压患者进行了研究。所有患者在服用β受体阻滞剂和另外两种治疗剂量的抗高血压药物时，有3次血压记录高于160/95 mmHg。通过对相关β受体阻滞剂进行间歇性尿液分析来检查依从性。这些难以控制的高血压患者分别接受单独使用纳多洛尔、纳多洛尔加吲达帕胺以及纳多洛尔加希帕胺治疗，每种治疗持续2个月，治疗顺序随机。目标是将血压降至160/95 mmHg以下。单独使用纳多洛尔时的仰卧血压（167/100 mmHg）与之前三种药物治疗方案时的血压（157/100 mmHg）相当，另外两种治疗更有效（分别为145/90 mmHg和148/93 mmHg）。6名患者出现低钾血症（血清钾低于3.5 mmol/l），但希帕胺组比吲达帕胺组更频繁出现。
